The largest database of trusted experimental protocols

Stata statistical software package version 12

Manufactured by StataCorp
Sourced in United States

STATA statistical software package version 12.0 is a comprehensive, integrated software package for data analysis, data management, and graphics. It provides a wide range of statistical and data management capabilities, including regression analysis, time-series analysis, and data visualization.

Automatically generated - may contain errors

19 protocols using stata statistical software package version 12

1

Meta-analysis of Hyperemesis Gravidarum and Helicobacter Pylori

Check if the same lab product or an alternative is used in the 5 most similar protocols
We used pooled odds ratio (OR) with its corresponding 95% confidence interval (CI) to estimate the strength of the association between HG and H. pylori infection. Post hoc subgroup analyses were also performed to explain the heterogeneity in results. Subgroups were explored as follows: detection of H. pylori infection (serum H. pylori IgG/IgM/IgA antibody by ELISA, stool antigen test, mucosal biopsy from endoscopy, or H. pylori genome by PCR), publication period (1996–2000, 2001–2005, 2006–2010, or 2011–2014), and region (Asia, North America, Europe, Africa, or Oceania).
The heterogeneity of the studies included in this meta-analysis was assessed using the Q statistic test and the I2 statistic test. The random-effects model was selected when P value < 0.1 or I2 > 50%; otherwise, the fixed-effects model was selected. Possible publication bias was evaluated by visual inspection of funnel plots and application of Begg's and Egger's test [11 (link)–15 (link)]. P values of less than 0.05 from Egger's test were considered statistically significant.
All statistical analyses were done with STATA statistical software package version 12.0 (2000; STATA Corp., College Station, TX, USA); P < 0.05 was identified as statistically significant.
+ Open protocol
+ Expand
2

Meta-analysis of Observational Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols
The collected information from each identified study include: the first author, year of publication, country, average age, OR, and 95 % CI, and adjusted factors. Two reviewers extracted the data from each study independently and finally verified the extracted data. The meta-analysis was performed using the Stata statistical software package, version 12.0 (StataCorp, College Station, Texas, USA). The random effect model was employed during all the analyses. The heterogeneity was assessed through the I2 statistic.
+ Open protocol
+ Expand
3

Meta-Analysis of Survival Outcomes

Check if the same lab product or an alternative is used in the 5 most similar protocols
Calculation for dichotomous variables was carried out using the risk ratio (RR) and their 95% confidence interval (CI) as the summary statistic. Interstudy heterogeneity among the included studies was evaluated by the I2 statistics.[6 (link)] Time-to-event data including the 3-year OS, 3-year progression-free survival (PFS), 5-year OS, and the 5-year PFS were extracted from individual trials. Pooled categorical comparisons were made by Chi-squared test. If the I2 was larger than 50%, implying significant statistical heterogeneity between studies, the random effects (DerSimonian-Laird method) model was adopted; in the presence of no observable interstudy heterogeneity (I2 < 50%), the fixed-effect model was applied. Two-sided P < 0.05 was considered statistically significant. Sensitivity analysis was performed to evaluate the stability of the results. Each study involved in the meta-analysis was removed each time to reflect the influence of the individual data set on the pooled effects. Evidence of publication bias was evaluated using the Begg's test[7 (link)] and Egger's test.[8 (link)] All analyses were performed using STATA statistical software package version 12.0 (STATA Corp., College Station, Texas, USA).
+ Open protocol
+ Expand
4

Smoking Prevalence and Cotinine Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Prevalence/percentage figures with 95% confidence intervals (95% CI) were calculated and chi-squared tests for associations between smoking and cohort, sex and residential region (ABC only) were done using a p-value less than 0.05 for statistical significance. Urinary cotinine was treated as a continuous measurement and all other variables were treated as categorical. Comparisons of cotinine levels between groups were done using the Wilcoxon rank-sum test. All statistical analyses were done using the Stata statistical software package, version 12.0 (StataCorp, College Station, TX).
+ Open protocol
+ Expand
5

Predictive Role of CRP in STS

Check if the same lab product or an alternative is used in the 5 most similar protocols
Statistical analysis was carried out using the STATA statistical software package version 12.0 (Stata Corporation, College Station, TX). Combined HRs and Forrest plots were used to estimate the predictive role of CRP levels in STS patients. The Cochrane Q test (P<0.05 indicated a high level of heterogeneity) and I2 (values of 25%, 50% and 75% corresponding to low, moderate, and high degrees of heterogeneity, respectively) was used to evaluate the heterogeneity between eligible studies. When homogeneity was good, a fixed-effect model was used; When heterogeneity was high, a random-effect model was used [24 (link)]. An observed HR > 1 indicated worse outcome for higher CRP levels. Begg’s test and Egger’s test on asymmetry of funnel plot were performed to test any existing publication bias. If evidence of publication bias was found, trim and fill method was adopted to check and revise the combined HRs [25 (link)]. Meta-regression analyses and subgroup analyses were performed to investigate the sources of heterogeneity [26 (link)]. Sensitivity analysis was also conducted to assess the influence of each individual study on the strength and stability of the combined HRs. All statistical tests were two-tailed and p < 0.05 was considered statistically significant.
+ Open protocol
+ Expand
6

Prognostic Value of SPARC in Pancreatic Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
The primary outcome was OS associated with SPARC expression in patients with pancreatic cancer. HR and 95% CI were used to be the effect measure of interest. A combined HR>1, with its 95% CI did not overlap 1, indicated a worse survival for the group with high SPARC expression. The heterogeneity among studies was measured using the Q and I2 test. A random or Fixed model was used according the heterogeneity analysis. A random effect model was applied if I2≧50%; the fixed effect model was selected if I2<50%. When I2≧50%, subgroup analyses would be carried out. A P < 0.05 indicates a significant factor contributing to the observed heterogeneity. The latent publication bias was assessed by a funnel plot and Egger’s linear regression test, and a value <0.05 indicated an inevitable significant publication bias[19 (link)]. All statistical tests were two-tailed and P<0.05 was considered statistically significant. All the analyses were conducted by Review Manager software version 5.3 (The Cochrane Collaboration) and STATA statistical software package version 12.0 (Stata Corporation, College Station, TX).
+ Open protocol
+ Expand
7

Diagnostic Test Evaluation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Sensitivity and specificity of diagnostic tests were calculated according to the following formulas: SE = TP/(TP + FN)*100, SP = TN/(TN + FP)*100; PPV, NPV and accuracy was calculated as follows: PPV = TP/P, NPV = TN/N, Accuracy = TP/(TP + TN)*100. FN: False negative; FP: False positive; N: Negative; NPV: Negative predict value; P: Positive; PPV: Positive predict value; SE: Sensitivity; SP: Specificity; TN: True negative; TP: True positive.
All of presented dHMGS dye intensity traces show a representative outcome form an individual run from gastric biopsy specimen selected from total dataset subjected to analysis. Data were statistically analyzed by χ2 test using Stata statistical software package version 12.0 (StataCorp College Station, TX, USA). Additionally, Gwet’s AC1 values were calculated to measure the detection agreement of dHMGS assay with sequencing using AgreeStat version 2011.3 (Advanced Analytics, MD, USA) [8 (link)]. The benchmark scales for Gwet’s AC1 values was based on the Landis and Koch’s criteria [9 (link)]. The H. pylori distribution of different groups was analyzed by Mann–Whitney rank-sum test for two variables and Kruskal–Wallis H test for more than two variables. All of the above hypothesis tests were two-sided; and a two-tailed p-value of 0.05 or less was considered to indicate statistical significance.
+ Open protocol
+ Expand
8

Meta-analysis of Tenascin-C Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols
Meta-analysis was carried out using STATA statistical software package version 12.0 (STATA Corp, College Station, Texas). Pooled HRs and corresponding 95% CIs were calculated to evaluate the impact of TN-C expression on OS. The χ2-based Q test and I2 test were used to evaluate the heterogeneity across the studies. Random effect model was used for meta-analysis if there was significant heterogeneity (P ≤ .05, I2 ≥ 50%), otherwise, fixed effect model was used. Besides, subgroup analysis was performed to explore the sources of heterogeneity. Meanwhile, we used funnel plots and Begg’s bias test to analyze the publication bias in this study.20 (link)
+ Open protocol
+ Expand
9

Meta-analysis of Prognostic Biomarker PLR in Esophageal Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
HR and 95%CI were obtained directly from each literature or estimation according to the methods by Parmer et al [40 (link)]. A HR>1 indicated a worse prognosis in esophageal cancer patients with high expression of PLR. For each meta-analysis, Cochran’s Q test and Higgins I-squared statistic were undertaken to assess the heterogeneity of the included trials. I2>50% is considered as a measure of severe heterogeneity. Both fixed-effects (Mantel–Haenszel method) and random effects (DerSimonian–Laird method) models were used to calculate the pooled HRs and 95%CIs. The random-effects model was used if there was heterogeneity between literatures; otherwise, the fixed-effects model was adopted.
Subgroup analysis was conducted to explore and explain the diversity (heterogeneity) among the results of different studies. Publication bias was assessed by Begg’s funnel plot and Egger’s bias test [41 (link)]. All P values were two-tailed, A P<0.05 was considered statistical significant. Statistical analyses were performed using STATA statistical software package version 12.0 (STATA, College Station, TX, USA).
+ Open protocol
+ Expand
10

Berberine Inhibits Tumor Growth

Check if the same lab product or an alternative is used in the 5 most similar protocols
We carried out statistical analysis by using the Review Manager software (RevMan 5.3) and STATA statistical software package version 12.0 (Stata Corporation, College Station, TX). The primary outcomes were tumor volume, tumor weight, and tumor vessel density of BBR group compared with the control group. The secondary outcome was the change of body weight. Mean value and standard difference (SD) were used as summary statistics. Standard mean difference (SMD) was measured for continuous data. Linear regression and Pearson’s correlation analysis were used to study the The dose–response relationship between BBR and the four outcomes. The heterogeneity among studies was measured by using the I2 test. The latent publication bias was assessed by using a funnel plot. All statistical tests were two-tailed, and p < 0.05 was considered statistically significant.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!